INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42401, 27431, 'Dasatinib', 'Long QT Syndrome', 'Dasatinib has shown to prolong QT interval in a concentration-dependent manner.  Caution should be exercised specially in patients with congenital long QT syndrome, patients with hypokalemia, hypomagnesemia, or with history of arrhythmias and on antiarrhythmic medication.  Hypokalemia or hypomagnesemia should be corrected before starting treatment.  Patients at risk should be monitored with an EKG before treatment and periodically as clinically indicated.  Dose adjustments might be needed.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42402, 9026, 'Allopurinol', 'Bone Marrow Failure Disorders', 'Bone marrow suppression has been reported in patients receiving allopurinol; however, most of these patients were receiving concomitant medications with the known potential to cause such an effect.  The suppression has occurred from as early as 6 weeks to as long as 6 years after the initiation of allopurinol therapy.  Therapy with allopurinol should be administered cautiously to patients with or predisposed to bone marrow suppression.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42403, 11966, 'Allopurinol', 'Bone Marrow Failure Disorders', 'Bone marrow suppression has been reported in patients receiving allopurinol; however, most of these patients were receiving concomitant medications with the known potential to cause such an effect.  The suppression has occurred from as early as 6 weeks to as long as 6 years after the initiation of allopurinol therapy.  Therapy with allopurinol should be administered cautiously to patients with or predisposed to bone marrow suppression.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42404, 11967, 'Allopurinol', 'Bone Marrow Failure Disorders', 'Bone marrow suppression has been reported in patients receiving allopurinol; however, most of these patients were receiving concomitant medications with the known potential to cause such an effect.  The suppression has occurred from as early as 6 weeks to as long as 6 years after the initiation of allopurinol therapy.  Therapy with allopurinol should be administered cautiously to patients with or predisposed to bone marrow suppression.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42405, 12949, 'Allopurinol', 'Bone Marrow Failure Disorders', 'Bone marrow suppression has been reported in patients receiving allopurinol; however, most of these patients were receiving concomitant medications with the known potential to cause such an effect.  The suppression has occurred from as early as 6 weeks to as long as 6 years after the initiation of allopurinol therapy.  Therapy with allopurinol should be administered cautiously to patients with or predisposed to bone marrow suppression.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42406, 12950, 'Allopurinol', 'Bone Marrow Failure Disorders', 'Bone marrow suppression has been reported in patients receiving allopurinol; however, most of these patients were receiving concomitant medications with the known potential to cause such an effect.  The suppression has occurred from as early as 6 weeks to as long as 6 years after the initiation of allopurinol therapy.  Therapy with allopurinol should be administered cautiously to patients with or predisposed to bone marrow suppression.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42407, 16927, 'Allopurinol', 'Bone Marrow Failure Disorders', 'Bone marrow suppression has been reported in patients receiving allopurinol; however, most of these patients were receiving concomitant medications with the known potential to cause such an effect.  The suppression has occurred from as early as 6 weeks to as long as 6 years after the initiation of allopurinol therapy.  Therapy with allopurinol should be administered cautiously to patients with or predisposed to bone marrow suppression.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42408, 20483, 'Allopurinol', 'Bone Marrow Failure Disorders', 'Bone marrow suppression has been reported in patients receiving allopurinol; however, most of these patients were receiving concomitant medications with the known potential to cause such an effect.  The suppression has occurred from as early as 6 weeks to as long as 6 years after the initiation of allopurinol therapy.  Therapy with allopurinol should be administered cautiously to patients with or predisposed to bone marrow suppression.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42409, 21719, 'Allopurinol', 'Bone Marrow Failure Disorders', 'Bone marrow suppression has been reported in patients receiving allopurinol; however, most of these patients were receiving concomitant medications with the known potential to cause such an effect.  The suppression has occurred from as early as 6 weeks to as long as 6 years after the initiation of allopurinol therapy.  Therapy with allopurinol should be administered cautiously to patients with or predisposed to bone marrow suppression.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42410, 21720, 'Allopurinol', 'Bone Marrow Failure Disorders', 'Bone marrow suppression has been reported in patients receiving allopurinol; however, most of these patients were receiving concomitant medications with the known potential to cause such an effect.  The suppression has occurred from as early as 6 weeks to as long as 6 years after the initiation of allopurinol therapy.  Therapy with allopurinol should be administered cautiously to patients with or predisposed to bone marrow suppression.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42411, 23758, 'Allopurinol', 'Bone Marrow Failure Disorders', 'Bone marrow suppression has been reported in patients receiving allopurinol; however, most of these patients were receiving concomitant medications with the known potential to cause such an effect.  The suppression has occurred from as early as 6 weeks to as long as 6 years after the initiation of allopurinol therapy.  Therapy with allopurinol should be administered cautiously to patients with or predisposed to bone marrow suppression.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42412, 25506, 'Allopurinol', 'Bone Marrow Failure Disorders', 'Bone marrow suppression has been reported in patients receiving allopurinol; however, most of these patients were receiving concomitant medications with the known potential to cause such an effect.  The suppression has occurred from as early as 6 weeks to as long as 6 years after the initiation of allopurinol therapy.  Therapy with allopurinol should be administered cautiously to patients with or predisposed to bone marrow suppression.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42413, 9026, 'Allopurinol', 'Dehydration', 'Adequate hydration is necessary during therapy with allopurinol to prevent both the formation of xanthine calculi and renal precipitation of urates when concomitant uricosuric agents are given.  Patients who are dehydrated (e.g., due to severe diarrhea or vomiting) may be at increased risk and should be encouraged to consume additional amounts of liquid or given intravenous fluid.  In general, fluid intake sufficient to yield a daily urinary output of at least 2 liters is recommended.  Maintenance of a slightly alkaline or neutral urine is also desirable.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42414, 11966, 'Allopurinol', 'Dehydration', 'Adequate hydration is necessary during therapy with allopurinol to prevent both the formation of xanthine calculi and renal precipitation of urates when concomitant uricosuric agents are given.  Patients who are dehydrated (e.g., due to severe diarrhea or vomiting) may be at increased risk and should be encouraged to consume additional amounts of liquid or given intravenous fluid.  In general, fluid intake sufficient to yield a daily urinary output of at least 2 liters is recommended.  Maintenance of a slightly alkaline or neutral urine is also desirable.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42415, 11967, 'Allopurinol', 'Dehydration', 'Adequate hydration is necessary during therapy with allopurinol to prevent both the formation of xanthine calculi and renal precipitation of urates when concomitant uricosuric agents are given.  Patients who are dehydrated (e.g., due to severe diarrhea or vomiting) may be at increased risk and should be encouraged to consume additional amounts of liquid or given intravenous fluid.  In general, fluid intake sufficient to yield a daily urinary output of at least 2 liters is recommended.  Maintenance of a slightly alkaline or neutral urine is also desirable.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42416, 12949, 'Allopurinol', 'Dehydration', 'Adequate hydration is necessary during therapy with allopurinol to prevent both the formation of xanthine calculi and renal precipitation of urates when concomitant uricosuric agents are given.  Patients who are dehydrated (e.g., due to severe diarrhea or vomiting) may be at increased risk and should be encouraged to consume additional amounts of liquid or given intravenous fluid.  In general, fluid intake sufficient to yield a daily urinary output of at least 2 liters is recommended.  Maintenance of a slightly alkaline or neutral urine is also desirable.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42417, 12950, 'Allopurinol', 'Dehydration', 'Adequate hydration is necessary during therapy with allopurinol to prevent both the formation of xanthine calculi and renal precipitation of urates when concomitant uricosuric agents are given.  Patients who are dehydrated (e.g., due to severe diarrhea or vomiting) may be at increased risk and should be encouraged to consume additional amounts of liquid or given intravenous fluid.  In general, fluid intake sufficient to yield a daily urinary output of at least 2 liters is recommended.  Maintenance of a slightly alkaline or neutral urine is also desirable.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42418, 16927, 'Allopurinol', 'Dehydration', 'Adequate hydration is necessary during therapy with allopurinol to prevent both the formation of xanthine calculi and renal precipitation of urates when concomitant uricosuric agents are given.  Patients who are dehydrated (e.g., due to severe diarrhea or vomiting) may be at increased risk and should be encouraged to consume additional amounts of liquid or given intravenous fluid.  In general, fluid intake sufficient to yield a daily urinary output of at least 2 liters is recommended.  Maintenance of a slightly alkaline or neutral urine is also desirable.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42419, 20483, 'Allopurinol', 'Dehydration', 'Adequate hydration is necessary during therapy with allopurinol to prevent both the formation of xanthine calculi and renal precipitation of urates when concomitant uricosuric agents are given.  Patients who are dehydrated (e.g., due to severe diarrhea or vomiting) may be at increased risk and should be encouraged to consume additional amounts of liquid or given intravenous fluid.  In general, fluid intake sufficient to yield a daily urinary output of at least 2 liters is recommended.  Maintenance of a slightly alkaline or neutral urine is also desirable.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42420, 21719, 'Allopurinol', 'Dehydration', 'Adequate hydration is necessary during therapy with allopurinol to prevent both the formation of xanthine calculi and renal precipitation of urates when concomitant uricosuric agents are given.  Patients who are dehydrated (e.g., due to severe diarrhea or vomiting) may be at increased risk and should be encouraged to consume additional amounts of liquid or given intravenous fluid.  In general, fluid intake sufficient to yield a daily urinary output of at least 2 liters is recommended.  Maintenance of a slightly alkaline or neutral urine is also desirable.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42421, 21720, 'Allopurinol', 'Dehydration', 'Adequate hydration is necessary during therapy with allopurinol to prevent both the formation of xanthine calculi and renal precipitation of urates when concomitant uricosuric agents are given.  Patients who are dehydrated (e.g., due to severe diarrhea or vomiting) may be at increased risk and should be encouraged to consume additional amounts of liquid or given intravenous fluid.  In general, fluid intake sufficient to yield a daily urinary output of at least 2 liters is recommended.  Maintenance of a slightly alkaline or neutral urine is also desirable.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42422, 23758, 'Allopurinol', 'Dehydration', 'Adequate hydration is necessary during therapy with allopurinol to prevent both the formation of xanthine calculi and renal precipitation of urates when concomitant uricosuric agents are given.  Patients who are dehydrated (e.g., due to severe diarrhea or vomiting) may be at increased risk and should be encouraged to consume additional amounts of liquid or given intravenous fluid.  In general, fluid intake sufficient to yield a daily urinary output of at least 2 liters is recommended.  Maintenance of a slightly alkaline or neutral urine is also desirable.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42423, 25506, 'Allopurinol', 'Dehydration', 'Adequate hydration is necessary during therapy with allopurinol to prevent both the formation of xanthine calculi and renal precipitation of urates when concomitant uricosuric agents are given.  Patients who are dehydrated (e.g., due to severe diarrhea or vomiting) may be at increased risk and should be encouraged to consume additional amounts of liquid or given intravenous fluid.  In general, fluid intake sufficient to yield a daily urinary output of at least 2 liters is recommended.  Maintenance of a slightly alkaline or neutral urine is also desirable.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42424, 9026, 'Allopurinol', 'Liver Diseases', 'The use of allopurinol has infrequently been associated with asymptomatic elevations of serum transaminase and alkaline phosphatase levels.  Isolated cases of cholestatic jaundice, hepatic necrosis, granulomatous hepatitis, and hepatomegaly have also been reported.  Therapy with allopurinol should be administered cautiously in patients with liver disease.  Periodic monitoring of liver function tests is recommended in these patients during the early stages of therapy.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42425, 11966, 'Allopurinol', 'Liver Diseases', 'The use of allopurinol has infrequently been associated with asymptomatic elevations of serum transaminase and alkaline phosphatase levels.  Isolated cases of cholestatic jaundice, hepatic necrosis, granulomatous hepatitis, and hepatomegaly have also been reported.  Therapy with allopurinol should be administered cautiously in patients with liver disease.  Periodic monitoring of liver function tests is recommended in these patients during the early stages of therapy.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42426, 11967, 'Allopurinol', 'Liver Diseases', 'The use of allopurinol has infrequently been associated with asymptomatic elevations of serum transaminase and alkaline phosphatase levels.  Isolated cases of cholestatic jaundice, hepatic necrosis, granulomatous hepatitis, and hepatomegaly have also been reported.  Therapy with allopurinol should be administered cautiously in patients with liver disease.  Periodic monitoring of liver function tests is recommended in these patients during the early stages of therapy.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42427, 12949, 'Allopurinol', 'Liver Diseases', 'The use of allopurinol has infrequently been associated with asymptomatic elevations of serum transaminase and alkaline phosphatase levels.  Isolated cases of cholestatic jaundice, hepatic necrosis, granulomatous hepatitis, and hepatomegaly have also been reported.  Therapy with allopurinol should be administered cautiously in patients with liver disease.  Periodic monitoring of liver function tests is recommended in these patients during the early stages of therapy.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42428, 12950, 'Allopurinol', 'Liver Diseases', 'The use of allopurinol has infrequently been associated with asymptomatic elevations of serum transaminase and alkaline phosphatase levels.  Isolated cases of cholestatic jaundice, hepatic necrosis, granulomatous hepatitis, and hepatomegaly have also been reported.  Therapy with allopurinol should be administered cautiously in patients with liver disease.  Periodic monitoring of liver function tests is recommended in these patients during the early stages of therapy.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42429, 16927, 'Allopurinol', 'Liver Diseases', 'The use of allopurinol has infrequently been associated with asymptomatic elevations of serum transaminase and alkaline phosphatase levels.  Isolated cases of cholestatic jaundice, hepatic necrosis, granulomatous hepatitis, and hepatomegaly have also been reported.  Therapy with allopurinol should be administered cautiously in patients with liver disease.  Periodic monitoring of liver function tests is recommended in these patients during the early stages of therapy.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42430, 20483, 'Allopurinol', 'Liver Diseases', 'The use of allopurinol has infrequently been associated with asymptomatic elevations of serum transaminase and alkaline phosphatase levels.  Isolated cases of cholestatic jaundice, hepatic necrosis, granulomatous hepatitis, and hepatomegaly have also been reported.  Therapy with allopurinol should be administered cautiously in patients with liver disease.  Periodic monitoring of liver function tests is recommended in these patients during the early stages of therapy.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42431, 21719, 'Allopurinol', 'Liver Diseases', 'The use of allopurinol has infrequently been associated with asymptomatic elevations of serum transaminase and alkaline phosphatase levels.  Isolated cases of cholestatic jaundice, hepatic necrosis, granulomatous hepatitis, and hepatomegaly have also been reported.  Therapy with allopurinol should be administered cautiously in patients with liver disease.  Periodic monitoring of liver function tests is recommended in these patients during the early stages of therapy.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42432, 21720, 'Allopurinol', 'Liver Diseases', 'The use of allopurinol has infrequently been associated with asymptomatic elevations of serum transaminase and alkaline phosphatase levels.  Isolated cases of cholestatic jaundice, hepatic necrosis, granulomatous hepatitis, and hepatomegaly have also been reported.  Therapy with allopurinol should be administered cautiously in patients with liver disease.  Periodic monitoring of liver function tests is recommended in these patients during the early stages of therapy.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42433, 23758, 'Allopurinol', 'Liver Diseases', 'The use of allopurinol has infrequently been associated with asymptomatic elevations of serum transaminase and alkaline phosphatase levels.  Isolated cases of cholestatic jaundice, hepatic necrosis, granulomatous hepatitis, and hepatomegaly have also been reported.  Therapy with allopurinol should be administered cautiously in patients with liver disease.  Periodic monitoring of liver function tests is recommended in these patients during the early stages of therapy.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42434, 25506, 'Allopurinol', 'Liver Diseases', 'The use of allopurinol has infrequently been associated with asymptomatic elevations of serum transaminase and alkaline phosphatase levels.  Isolated cases of cholestatic jaundice, hepatic necrosis, granulomatous hepatitis, and hepatomegaly have also been reported.  Therapy with allopurinol should be administered cautiously in patients with liver disease.  Periodic monitoring of liver function tests is recommended in these patients during the early stages of therapy.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42435, 9026, 'Allopurinol', 'Kidney Diseases', 'Patients with decreased renal function require lower dosages of allopurinol than normal to control serum urate levels.  Therapy should be initiated at reduced dosages with smaller incremental changes in such patients.  Additionally, individuals with preexisting renal disease or poor urate clearance have demonstrated a rise in BUN during therapy with allopurinol.  Renal failure has also been observed among some with hyperuricemia secondary to neoplastic diseases.  Renal function should be monitored during the initial stages of therapy, and the dosage reduced or the drug withdrawn if necessary.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42436, 11966, 'Allopurinol', 'Kidney Diseases', 'Patients with decreased renal function require lower dosages of allopurinol than normal to control serum urate levels.  Therapy should be initiated at reduced dosages with smaller incremental changes in such patients.  Additionally, individuals with preexisting renal disease or poor urate clearance have demonstrated a rise in BUN during therapy with allopurinol.  Renal failure has also been observed among some with hyperuricemia secondary to neoplastic diseases.  Renal function should be monitored during the initial stages of therapy, and the dosage reduced or the drug withdrawn if necessary.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42437, 11967, 'Allopurinol', 'Kidney Diseases', 'Patients with decreased renal function require lower dosages of allopurinol than normal to control serum urate levels.  Therapy should be initiated at reduced dosages with smaller incremental changes in such patients.  Additionally, individuals with preexisting renal disease or poor urate clearance have demonstrated a rise in BUN during therapy with allopurinol.  Renal failure has also been observed among some with hyperuricemia secondary to neoplastic diseases.  Renal function should be monitored during the initial stages of therapy, and the dosage reduced or the drug withdrawn if necessary.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42438, 12949, 'Allopurinol', 'Kidney Diseases', 'Patients with decreased renal function require lower dosages of allopurinol than normal to control serum urate levels.  Therapy should be initiated at reduced dosages with smaller incremental changes in such patients.  Additionally, individuals with preexisting renal disease or poor urate clearance have demonstrated a rise in BUN during therapy with allopurinol.  Renal failure has also been observed among some with hyperuricemia secondary to neoplastic diseases.  Renal function should be monitored during the initial stages of therapy, and the dosage reduced or the drug withdrawn if necessary.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42439, 12950, 'Allopurinol', 'Kidney Diseases', 'Patients with decreased renal function require lower dosages of allopurinol than normal to control serum urate levels.  Therapy should be initiated at reduced dosages with smaller incremental changes in such patients.  Additionally, individuals with preexisting renal disease or poor urate clearance have demonstrated a rise in BUN during therapy with allopurinol.  Renal failure has also been observed among some with hyperuricemia secondary to neoplastic diseases.  Renal function should be monitored during the initial stages of therapy, and the dosage reduced or the drug withdrawn if necessary.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42440, 16927, 'Allopurinol', 'Kidney Diseases', 'Patients with decreased renal function require lower dosages of allopurinol than normal to control serum urate levels.  Therapy should be initiated at reduced dosages with smaller incremental changes in such patients.  Additionally, individuals with preexisting renal disease or poor urate clearance have demonstrated a rise in BUN during therapy with allopurinol.  Renal failure has also been observed among some with hyperuricemia secondary to neoplastic diseases.  Renal function should be monitored during the initial stages of therapy, and the dosage reduced or the drug withdrawn if necessary.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42441, 20483, 'Allopurinol', 'Kidney Diseases', 'Patients with decreased renal function require lower dosages of allopurinol than normal to control serum urate levels.  Therapy should be initiated at reduced dosages with smaller incremental changes in such patients.  Additionally, individuals with preexisting renal disease or poor urate clearance have demonstrated a rise in BUN during therapy with allopurinol.  Renal failure has also been observed among some with hyperuricemia secondary to neoplastic diseases.  Renal function should be monitored during the initial stages of therapy, and the dosage reduced or the drug withdrawn if necessary.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42442, 21719, 'Allopurinol', 'Kidney Diseases', 'Patients with decreased renal function require lower dosages of allopurinol than normal to control serum urate levels.  Therapy should be initiated at reduced dosages with smaller incremental changes in such patients.  Additionally, individuals with preexisting renal disease or poor urate clearance have demonstrated a rise in BUN during therapy with allopurinol.  Renal failure has also been observed among some with hyperuricemia secondary to neoplastic diseases.  Renal function should be monitored during the initial stages of therapy, and the dosage reduced or the drug withdrawn if necessary.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42443, 21720, 'Allopurinol', 'Kidney Diseases', 'Patients with decreased renal function require lower dosages of allopurinol than normal to control serum urate levels.  Therapy should be initiated at reduced dosages with smaller incremental changes in such patients.  Additionally, individuals with preexisting renal disease or poor urate clearance have demonstrated a rise in BUN during therapy with allopurinol.  Renal failure has also been observed among some with hyperuricemia secondary to neoplastic diseases.  Renal function should be monitored during the initial stages of therapy, and the dosage reduced or the drug withdrawn if necessary.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42444, 23758, 'Allopurinol', 'Kidney Diseases', 'Patients with decreased renal function require lower dosages of allopurinol than normal to control serum urate levels.  Therapy should be initiated at reduced dosages with smaller incremental changes in such patients.  Additionally, individuals with preexisting renal disease or poor urate clearance have demonstrated a rise in BUN during therapy with allopurinol.  Renal failure has also been observed among some with hyperuricemia secondary to neoplastic diseases.  Renal function should be monitored during the initial stages of therapy, and the dosage reduced or the drug withdrawn if necessary.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42445, 25506, 'Allopurinol', 'Kidney Diseases', 'Patients with decreased renal function require lower dosages of allopurinol than normal to control serum urate levels.  Therapy should be initiated at reduced dosages with smaller incremental changes in such patients.  Additionally, individuals with preexisting renal disease or poor urate clearance have demonstrated a rise in BUN during therapy with allopurinol.  Renal failure has also been observed among some with hyperuricemia secondary to neoplastic diseases.  Renal function should be monitored during the initial stages of therapy, and the dosage reduced or the drug withdrawn if necessary.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42446, 17122, 'Daunorubicin', 'Heart Failure', 'Daunorubicin can cause myocardial toxicity leading to congestive heart failure.  Patients with preexisting heart disease or prior anthracycline therapy are at increased risk of congestive heart failure.  The benefit-to-risk ratio of daunorubicin therapy in such patients should be weighed before starting treatment.  The incidence of drug-induced congestive heart failure in adults is increased when the total cumulative dose of daunorubicin exceeds 550/mg/m2.  An electrocardiogram and/or determination of systolic ejection fraction prior to each course of therapy is recommended.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42447, 17123, 'Daunorubicin', 'Heart Failure', 'Daunorubicin can cause myocardial toxicity leading to congestive heart failure.  Patients with preexisting heart disease or prior anthracycline therapy are at increased risk of congestive heart failure.  The benefit-to-risk ratio of daunorubicin therapy in such patients should be weighed before starting treatment.  The incidence of drug-induced congestive heart failure in adults is increased when the total cumulative dose of daunorubicin exceeds 550/mg/m2.  An electrocardiogram and/or determination of systolic ejection fraction prior to each course of therapy is recommended.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42448, 17122, 'Daunorubicin', 'Infections', 'Daunorubicin can induce severe myelosuppression at therapeutic doses.  The use of daunorubicin may be contraindicated in patients with known infectious diseases.  All patients should be instructed to immediately report any signs or symptoms suggesting infection such as fever, sore throat, or local infection during therapy with daunorubicin.  Close clinical monitoring of hematopoietic function is recommended.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42449, 17123, 'Daunorubicin', 'Infections', 'Daunorubicin can induce severe myelosuppression at therapeutic doses.  The use of daunorubicin may be contraindicated in patients with known infectious diseases.  All patients should be instructed to immediately report any signs or symptoms suggesting infection such as fever, sore throat, or local infection during therapy with daunorubicin.  Close clinical monitoring of hematopoietic function is recommended.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42450, 17122, 'Daunorubicin', 'Bone Marrow Failure Disorders', 'Daunorubicin hydrochloride is a potent bone marrow suppressant.  Suppression will occur in all patients given a therapeutic dose of the drug.  Therapy with daunorubicin hydrochloride should not be started in patients with preexisting drug-induced bone marrow suppression unless the benefit from such treatment warrants the risk.  Persistent, severe myelosuppression may result in superinfection or hemorrhage.  Patients should be instructed to immediately report any signs or symptoms suggesting bone marrow suppression such as fever, sore throat, local infection, or bleeding.  Close clinical monitory of hematopoietic function is recommended.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42451, 17123, 'Daunorubicin', 'Bone Marrow Failure Disorders', 'Daunorubicin hydrochloride is a potent bone marrow suppressant.  Suppression will occur in all patients given a therapeutic dose of the drug.  Therapy with daunorubicin hydrochloride should not be started in patients with preexisting drug-induced bone marrow suppression unless the benefit from such treatment warrants the risk.  Persistent, severe myelosuppression may result in superinfection or hemorrhage.  Patients should be instructed to immediately report any signs or symptoms suggesting bone marrow suppression such as fever, sore throat, local infection, or bleeding.  Close clinical monitory of hematopoietic function is recommended.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42452, 17122, 'Daunorubicin', 'Liver Diseases', 'Daunorubicin is extensively metabolized to a biologically active form within normal erythrocytes and leukocytes.  Further metabolism via reduction and conjugation has been demonstrated.  Approximately 40% of daunorubicin is eliminated in an active form by biliary excretion.  Patients with hepatic impairment may be at increased risk for toxicity. Therapy with daunorubicin should be administered cautiously and the dosage reduced in patients with compromised hepatic function.  Clinical evaluation of liver function prior to each course of treatment with daunorubicin is recommended.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42453, 17123, 'Daunorubicin', 'Liver Diseases', 'Daunorubicin is extensively metabolized to a biologically active form within normal erythrocytes and leukocytes.  Further metabolism via reduction and conjugation has been demonstrated.  Approximately 40% of daunorubicin is eliminated in an active form by biliary excretion.  Patients with hepatic impairment may be at increased risk for toxicity. Therapy with daunorubicin should be administered cautiously and the dosage reduced in patients with compromised hepatic function.  Clinical evaluation of liver function prior to each course of treatment with daunorubicin is recommended.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42454, 17122, 'Daunorubicin', 'Kidney Diseases', 'Approximately 25% of daunorubicin is eliminated in an active form in the urine.  Patient with renal impairment are at risk of greater toxicity noted at the recommended dose of daunorubicin.  Therapy with daunorubicin should be administered cautiously and at a reduced dosage in patients with significantly compromised renal function.  Clinical evaluation of renal function prior to each course of treatment is recommended.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42455, 17123, 'Daunorubicin', 'Kidney Diseases', 'Approximately 25% of daunorubicin is eliminated in an active form in the urine.  Patient with renal impairment are at risk of greater toxicity noted at the recommended dose of daunorubicin.  Therapy with daunorubicin should be administered cautiously and at a reduced dosage in patients with significantly compromised renal function.  Clinical evaluation of renal function prior to each course of treatment is recommended.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42456, 17120, 'Daratumumab', 'Pancytopenia', 'The use of daratumumab may increase neutropenia and thrombocytopenia induced by background therapy.  It is recommended to monitor complete blood cell counts periodically during treatment according to manufacturer''s prescribing information for background therapies.  Dose delay may be required to allow recovery of neutrophils and platelets and supportive care should be considered.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42457, 17121, 'Daratumumab', 'Pancytopenia', 'The use of daratumumab may increase neutropenia and thrombocytopenia induced by background therapy.  It is recommended to monitor complete blood cell counts periodically during treatment according to manufacturer''s prescribing information for background therapies.  Dose delay may be required to allow recovery of neutrophils and platelets and supportive care should be considered.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42458, 32709, 'Daratumumab', 'Pancytopenia', 'The use of daratumumab may increase neutropenia and thrombocytopenia induced by background therapy.  It is recommended to monitor complete blood cell counts periodically during treatment according to manufacturer''s prescribing information for background therapies.  Dose delay may be required to allow recovery of neutrophils and platelets and supportive care should be considered.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42459, 17120, 'Daratumumab', 'Cardiovascular Diseases', 'The use of daratumumab can cause severe infusion reactions, including bronchospasm, hypoxia, dyspnea, hypertension, laryngeal edema and pulmonary edema.  Caution should be taken in patients with a history of chronic obstructive pulmonary disease as they may require additional post-infusion medications to manage respiratory complications as appropriate.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42460, 17121, 'Daratumumab', 'Cardiovascular Diseases', 'The use of daratumumab can cause severe infusion reactions, including bronchospasm, hypoxia, dyspnea, hypertension, laryngeal edema and pulmonary edema.  Caution should be taken in patients with a history of chronic obstructive pulmonary disease as they may require additional post-infusion medications to manage respiratory complications as appropriate.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42461, 32709, 'Daratumumab', 'Cardiovascular Diseases', 'The use of daratumumab can cause severe infusion reactions, including bronchospasm, hypoxia, dyspnea, hypertension, laryngeal edema and pulmonary edema.  Caution should be taken in patients with a history of chronic obstructive pulmonary disease as they may require additional post-infusion medications to manage respiratory complications as appropriate.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42462, 3511, 'Deferoxamine', 'Kidney Diseases', 'The use of deferoxamine is contraindicated in patients with severe renal impairment or anuria.  Deferoxamine chelates iron and the complexes are primarily eliminated by the kidney.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42463, 17389, 'Deferoxamine', 'Kidney Diseases', 'The use of deferoxamine is contraindicated in patients with severe renal impairment or anuria.  Deferoxamine chelates iron and the complexes are primarily eliminated by the kidney.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42464, 3511, 'Deferoxamine', 'Auditory Diseases, Central', 'Neurotoxicity-related auditory abnormalities such as tinnitus and hearing loss including deafness have occurred after prolonged therapy or large doses of deferoxamine, or in patients with low ferritin levels.  Therapy with deferoxamine should be administered cautiously in patients with hearing impairment.  Hearing toxicity is usually reversible if detected early and deferoxamine discontinued.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42465, 17389, 'Deferoxamine', 'Auditory Diseases, Central', 'Neurotoxicity-related auditory abnormalities such as tinnitus and hearing loss including deafness have occurred after prolonged therapy or large doses of deferoxamine, or in patients with low ferritin levels.  Therapy with deferoxamine should be administered cautiously in patients with hearing impairment.  Hearing toxicity is usually reversible if detected early and deferoxamine discontinued.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42466, 3511, 'Deferoxamine', 'Hepatic Insufficiency', 'No studies of deferoxamine have been performed in patients with hepatic impairment.  Caution is advised.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42467, 17389, 'Deferoxamine', 'Hepatic Insufficiency', 'No studies of deferoxamine have been performed in patients with hepatic impairment.  Caution is advised.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42468, 3511, 'Deferoxamine', 'Toxic Optic Neuropathy', 'Deferoxamine may cause blurred vision, cataracts, decreased visual acuity, and impaired color, peripheral, and night vision.  Ocular toxicities have occurred after prolonged therapy, large doses, and in patients with decreased ferritin levels.  Therapy with deferoxamine should be administered cautiously in patients with or predisposed to visual defects.  Periodic examination of visual acuity is recommended in patients receiving long term deferoxamine therapy.  Ocular dysfunction is usually reversible if detected early and deferoxamine is withdrawn promptly.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42469, 17389, 'Deferoxamine', 'Toxic Optic Neuropathy', 'Deferoxamine may cause blurred vision, cataracts, decreased visual acuity, and impaired color, peripheral, and night vision.  Ocular toxicities have occurred after prolonged therapy, large doses, and in patients with decreased ferritin levels.  Therapy with deferoxamine should be administered cautiously in patients with or predisposed to visual defects.  Periodic examination of visual acuity is recommended in patients receiving long term deferoxamine therapy.  Ocular dysfunction is usually reversible if detected early and deferoxamine is withdrawn promptly.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42470, 3511, 'Deferoxamine', 'Respiratory Distress Syndrome', 'Acute respiratory distress syndrome has been described in patients with acute iron intoxication or thalassemia following treatment with excessively high intravenous doses of deferoxamine.  Caution is recommended when using deferoxamine in these patients.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42471, 17389, 'Deferoxamine', 'Respiratory Distress Syndrome', 'Acute respiratory distress syndrome has been described in patients with acute iron intoxication or thalassemia following treatment with excessively high intravenous doses of deferoxamine.  Caution is recommended when using deferoxamine in these patients.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42472, 17053, 'Decitabine', 'Liver Failure', 'There are no data on the use of decitabine in patients with hepatic dysfunction.  Decitabine should be used with caution in these patients.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42473, 17053, 'Decitabine', 'Hematologic Diseases', 'Treatment with decitabine is associated with neutropenia and thrombocytopenia.  It is recommended to consider the need for early institution of growth factors and/or antimicrobial agents for the prevention or treatment of infections in patients with myelodysplastic syndromes (MDS).  Complete blood and platelet counts should be performed as needed to monitor response and toxicity, but at a minimum, before each dosing cycle.  After administration of the recommended dosage for the first cycle, treatment for subsequent cycles should be adjusted according to manufacturer recommendations.  Myelosuppression and worsening neutropenia may occur more frequently in the first or second treatment cycles and may not necessarily indicate progression of underlying MDS.  Closely monitor patients at risk for hematological toxicities.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42474, 17053, 'Decitabine', 'Kidney Diseases', 'There are no data on the use of decitabine in patients with renal dysfunction.  Decitabine should be used with caution in these patients.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42475, 14130, 'Deferasirox', 'Bone Marrow Failure Disorders', 'The use of deferasirox is contraindicated in patients with platelet counts below 50 x 109/L.  Cytopenias, worsening anemia, and thrombocytopenia, including fatal events, have been reported in patients treated with deferasirox.  Preexisting hematologic disorders may increase this risk.  It is recommended to monitor blood counts in all patients and to interrupt treatment in patients who develop cytopenias until the cause of the cytopenia has been determined.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42476, 17181, 'Deferasirox', 'Bone Marrow Failure Disorders', 'The use of deferasirox is contraindicated in patients with platelet counts below 50 x 109/L.  Cytopenias, worsening anemia, and thrombocytopenia, including fatal events, have been reported in patients treated with deferasirox.  Preexisting hematologic disorders may increase this risk.  It is recommended to monitor blood counts in all patients and to interrupt treatment in patients who develop cytopenias until the cause of the cytopenia has been determined.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42477, 17182, 'Deferasirox', 'Bone Marrow Failure Disorders', 'The use of deferasirox is contraindicated in patients with platelet counts below 50 x 109/L.  Cytopenias, worsening anemia, and thrombocytopenia, including fatal events, have been reported in patients treated with deferasirox.  Preexisting hematologic disorders may increase this risk.  It is recommended to monitor blood counts in all patients and to interrupt treatment in patients who develop cytopenias until the cause of the cytopenia has been determined.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42478, 17183, 'Deferasirox', 'Bone Marrow Failure Disorders', 'The use of deferasirox is contraindicated in patients with platelet counts below 50 x 109/L.  Cytopenias, worsening anemia, and thrombocytopenia, including fatal events, have been reported in patients treated with deferasirox.  Preexisting hematologic disorders may increase this risk.  It is recommended to monitor blood counts in all patients and to interrupt treatment in patients who develop cytopenias until the cause of the cytopenia has been determined.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42479, 21118, 'Deferasirox', 'Bone Marrow Failure Disorders', 'The use of deferasirox is contraindicated in patients with platelet counts below 50 x 109/L.  Cytopenias, worsening anemia, and thrombocytopenia, including fatal events, have been reported in patients treated with deferasirox.  Preexisting hematologic disorders may increase this risk.  It is recommended to monitor blood counts in all patients and to interrupt treatment in patients who develop cytopenias until the cause of the cytopenia has been determined.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42480, 21119, 'Deferasirox', 'Bone Marrow Failure Disorders', 'The use of deferasirox is contraindicated in patients with platelet counts below 50 x 109/L.  Cytopenias, worsening anemia, and thrombocytopenia, including fatal events, have been reported in patients treated with deferasirox.  Preexisting hematologic disorders may increase this risk.  It is recommended to monitor blood counts in all patients and to interrupt treatment in patients who develop cytopenias until the cause of the cytopenia has been determined.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42481, 21120, 'Deferasirox', 'Bone Marrow Failure Disorders', 'The use of deferasirox is contraindicated in patients with platelet counts below 50 x 109/L.  Cytopenias, worsening anemia, and thrombocytopenia, including fatal events, have been reported in patients treated with deferasirox.  Preexisting hematologic disorders may increase this risk.  It is recommended to monitor blood counts in all patients and to interrupt treatment in patients who develop cytopenias until the cause of the cytopenia has been determined.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42482, 25727, 'Deferasirox', 'Bone Marrow Failure Disorders', 'The use of deferasirox is contraindicated in patients with platelet counts below 50 x 109/L.  Cytopenias, worsening anemia, and thrombocytopenia, including fatal events, have been reported in patients treated with deferasirox.  Preexisting hematologic disorders may increase this risk.  It is recommended to monitor blood counts in all patients and to interrupt treatment in patients who develop cytopenias until the cause of the cytopenia has been determined.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42483, 25728, 'Deferasirox', 'Bone Marrow Failure Disorders', 'The use of deferasirox is contraindicated in patients with platelet counts below 50 x 109/L.  Cytopenias, worsening anemia, and thrombocytopenia, including fatal events, have been reported in patients treated with deferasirox.  Preexisting hematologic disorders may increase this risk.  It is recommended to monitor blood counts in all patients and to interrupt treatment in patients who develop cytopenias until the cause of the cytopenia has been determined.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42484, 25729, 'Deferasirox', 'Bone Marrow Failure Disorders', 'The use of deferasirox is contraindicated in patients with platelet counts below 50 x 109/L.  Cytopenias, worsening anemia, and thrombocytopenia, including fatal events, have been reported in patients treated with deferasirox.  Preexisting hematologic disorders may increase this risk.  It is recommended to monitor blood counts in all patients and to interrupt treatment in patients who develop cytopenias until the cause of the cytopenia has been determined.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42485, 26273, 'Deferasirox', 'Bone Marrow Failure Disorders', 'The use of deferasirox is contraindicated in patients with platelet counts below 50 x 109/L.  Cytopenias, worsening anemia, and thrombocytopenia, including fatal events, have been reported in patients treated with deferasirox.  Preexisting hematologic disorders may increase this risk.  It is recommended to monitor blood counts in all patients and to interrupt treatment in patients who develop cytopenias until the cause of the cytopenia has been determined.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42486, 14130, 'Deferasirox', 'Stevens-Johnson Syndrome', 'Fatal cases of severe cutaneous reactions, including Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and erythema multiforme have occurred in patients treated with deferasirox.  The risk of other skin reactions cannot be excluded.  It is recommended that if SJS or TEN is suspected to interrupt therapy until the etiology of the reaction has been determined, and if SJS or TEN is confirmed to permanently discontinue treatment with deferasirox.  Monitor patients for the development of these severe cutaneous reactions, discontinue deferasirox if clinically appropriate and do not reintroduce therapy.  For severe cases of rash, interrupt treatment and consider reintroducing therapy after resolution of the rash at a lower dose with dose escalation as appropriate.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42487, 17181, 'Deferasirox', 'Stevens-Johnson Syndrome', 'Fatal cases of severe cutaneous reactions, including Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and erythema multiforme have occurred in patients treated with deferasirox.  The risk of other skin reactions cannot be excluded.  It is recommended that if SJS or TEN is suspected to interrupt therapy until the etiology of the reaction has been determined, and if SJS or TEN is confirmed to permanently discontinue treatment with deferasirox.  Monitor patients for the development of these severe cutaneous reactions, discontinue deferasirox if clinically appropriate and do not reintroduce therapy.  For severe cases of rash, interrupt treatment and consider reintroducing therapy after resolution of the rash at a lower dose with dose escalation as appropriate.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42488, 17182, 'Deferasirox', 'Stevens-Johnson Syndrome', 'Fatal cases of severe cutaneous reactions, including Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and erythema multiforme have occurred in patients treated with deferasirox.  The risk of other skin reactions cannot be excluded.  It is recommended that if SJS or TEN is suspected to interrupt therapy until the etiology of the reaction has been determined, and if SJS or TEN is confirmed to permanently discontinue treatment with deferasirox.  Monitor patients for the development of these severe cutaneous reactions, discontinue deferasirox if clinically appropriate and do not reintroduce therapy.  For severe cases of rash, interrupt treatment and consider reintroducing therapy after resolution of the rash at a lower dose with dose escalation as appropriate.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42489, 17183, 'Deferasirox', 'Stevens-Johnson Syndrome', 'Fatal cases of severe cutaneous reactions, including Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and erythema multiforme have occurred in patients treated with deferasirox.  The risk of other skin reactions cannot be excluded.  It is recommended that if SJS or TEN is suspected to interrupt therapy until the etiology of the reaction has been determined, and if SJS or TEN is confirmed to permanently discontinue treatment with deferasirox.  Monitor patients for the development of these severe cutaneous reactions, discontinue deferasirox if clinically appropriate and do not reintroduce therapy.  For severe cases of rash, interrupt treatment and consider reintroducing therapy after resolution of the rash at a lower dose with dose escalation as appropriate.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42490, 21118, 'Deferasirox', 'Stevens-Johnson Syndrome', 'Fatal cases of severe cutaneous reactions, including Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and erythema multiforme have occurred in patients treated with deferasirox.  The risk of other skin reactions cannot be excluded.  It is recommended that if SJS or TEN is suspected to interrupt therapy until the etiology of the reaction has been determined, and if SJS or TEN is confirmed to permanently discontinue treatment with deferasirox.  Monitor patients for the development of these severe cutaneous reactions, discontinue deferasirox if clinically appropriate and do not reintroduce therapy.  For severe cases of rash, interrupt treatment and consider reintroducing therapy after resolution of the rash at a lower dose with dose escalation as appropriate.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42491, 21119, 'Deferasirox', 'Stevens-Johnson Syndrome', 'Fatal cases of severe cutaneous reactions, including Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and erythema multiforme have occurred in patients treated with deferasirox.  The risk of other skin reactions cannot be excluded.  It is recommended that if SJS or TEN is suspected to interrupt therapy until the etiology of the reaction has been determined, and if SJS or TEN is confirmed to permanently discontinue treatment with deferasirox.  Monitor patients for the development of these severe cutaneous reactions, discontinue deferasirox if clinically appropriate and do not reintroduce therapy.  For severe cases of rash, interrupt treatment and consider reintroducing therapy after resolution of the rash at a lower dose with dose escalation as appropriate.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42492, 21120, 'Deferasirox', 'Stevens-Johnson Syndrome', 'Fatal cases of severe cutaneous reactions, including Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and erythema multiforme have occurred in patients treated with deferasirox.  The risk of other skin reactions cannot be excluded.  It is recommended that if SJS or TEN is suspected to interrupt therapy until the etiology of the reaction has been determined, and if SJS or TEN is confirmed to permanently discontinue treatment with deferasirox.  Monitor patients for the development of these severe cutaneous reactions, discontinue deferasirox if clinically appropriate and do not reintroduce therapy.  For severe cases of rash, interrupt treatment and consider reintroducing therapy after resolution of the rash at a lower dose with dose escalation as appropriate.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42493, 25727, 'Deferasirox', 'Stevens-Johnson Syndrome', 'Fatal cases of severe cutaneous reactions, including Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and erythema multiforme have occurred in patients treated with deferasirox.  The risk of other skin reactions cannot be excluded.  It is recommended that if SJS or TEN is suspected to interrupt therapy until the etiology of the reaction has been determined, and if SJS or TEN is confirmed to permanently discontinue treatment with deferasirox.  Monitor patients for the development of these severe cutaneous reactions, discontinue deferasirox if clinically appropriate and do not reintroduce therapy.  For severe cases of rash, interrupt treatment and consider reintroducing therapy after resolution of the rash at a lower dose with dose escalation as appropriate.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42494, 25728, 'Deferasirox', 'Stevens-Johnson Syndrome', 'Fatal cases of severe cutaneous reactions, including Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and erythema multiforme have occurred in patients treated with deferasirox.  The risk of other skin reactions cannot be excluded.  It is recommended that if SJS or TEN is suspected to interrupt therapy until the etiology of the reaction has been determined, and if SJS or TEN is confirmed to permanently discontinue treatment with deferasirox.  Monitor patients for the development of these severe cutaneous reactions, discontinue deferasirox if clinically appropriate and do not reintroduce therapy.  For severe cases of rash, interrupt treatment and consider reintroducing therapy after resolution of the rash at a lower dose with dose escalation as appropriate.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42495, 25729, 'Deferasirox', 'Stevens-Johnson Syndrome', 'Fatal cases of severe cutaneous reactions, including Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and erythema multiforme have occurred in patients treated with deferasirox.  The risk of other skin reactions cannot be excluded.  It is recommended that if SJS or TEN is suspected to interrupt therapy until the etiology of the reaction has been determined, and if SJS or TEN is confirmed to permanently discontinue treatment with deferasirox.  Monitor patients for the development of these severe cutaneous reactions, discontinue deferasirox if clinically appropriate and do not reintroduce therapy.  For severe cases of rash, interrupt treatment and consider reintroducing therapy after resolution of the rash at a lower dose with dose escalation as appropriate.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42496, 26273, 'Deferasirox', 'Stevens-Johnson Syndrome', 'Fatal cases of severe cutaneous reactions, including Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and erythema multiforme have occurred in patients treated with deferasirox.  The risk of other skin reactions cannot be excluded.  It is recommended that if SJS or TEN is suspected to interrupt therapy until the etiology of the reaction has been determined, and if SJS or TEN is confirmed to permanently discontinue treatment with deferasirox.  Monitor patients for the development of these severe cutaneous reactions, discontinue deferasirox if clinically appropriate and do not reintroduce therapy.  For severe cases of rash, interrupt treatment and consider reintroducing therapy after resolution of the rash at a lower dose with dose escalation as appropriate.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42497, 14130, 'Deferasirox', 'Hepatic Insufficiency', 'The use of deferasirox should be avoided in patients with severe hepatic impairment.  The starting dose of deferasirox should be reduced by 50% in patients with moderate hepatic impairment.  It is recommended to measure serum transaminases and bilirubin in all patients prior to initiating treatment, every 2 weeks during the first month, and at least monthly or more frequently as clinically appropriate.  Closely monitor patients with mild or moderate hepatic impairment for efficacy and adverse reactions that may require dose titration.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42498, 17181, 'Deferasirox', 'Hepatic Insufficiency', 'The use of deferasirox should be avoided in patients with severe hepatic impairment.  The starting dose of deferasirox should be reduced by 50% in patients with moderate hepatic impairment.  It is recommended to measure serum transaminases and bilirubin in all patients prior to initiating treatment, every 2 weeks during the first month, and at least monthly or more frequently as clinically appropriate.  Closely monitor patients with mild or moderate hepatic impairment for efficacy and adverse reactions that may require dose titration.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42499, 17182, 'Deferasirox', 'Hepatic Insufficiency', 'The use of deferasirox should be avoided in patients with severe hepatic impairment.  The starting dose of deferasirox should be reduced by 50% in patients with moderate hepatic impairment.  It is recommended to measure serum transaminases and bilirubin in all patients prior to initiating treatment, every 2 weeks during the first month, and at least monthly or more frequently as clinically appropriate.  Closely monitor patients with mild or moderate hepatic impairment for efficacy and adverse reactions that may require dose titration.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42500, 17183, 'Deferasirox', 'Hepatic Insufficiency', 'The use of deferasirox should be avoided in patients with severe hepatic impairment.  The starting dose of deferasirox should be reduced by 50% in patients with moderate hepatic impairment.  It is recommended to measure serum transaminases and bilirubin in all patients prior to initiating treatment, every 2 weeks during the first month, and at least monthly or more frequently as clinically appropriate.  Closely monitor patients with mild or moderate hepatic impairment for efficacy and adverse reactions that may require dose titration.', '3', '', 'DDInter', 0);
